natgillin/translations-raw huggingface dataset:
Of the 42 patients who were non-responders at week 24, confirmed culture conversion after week 24 (i.e., after bedaquiline dosing ended but the background regimen was continued) occurred in 9 patients (21.4%) and was maintained at week 120.
Od 42 bolesnika koji nisu odgovorili u tjednu 24, potvrđena konverzija kulture nakon tjedna 24 (tj. nakon što je završilo doziranje bedakilina, ali je nastavljeno osnovno liječenje) javila se je u 9 bolesnika (21,4%) i bila je zadržana u tjednu 120.
Of the 44 patients taking ritonavir oral solution, 27 switched to the 100 mg capsule formulation and exceeded the weight-based ritonavir dose without changes in observed safety.
44 bolesnika koji su uzimali ritonavir oralnu otopinu, njih 27 prešlo je na 100 mg kapsule i time prešlo preporučeno doziranje na temelju tjelesne težine, a da pri tome nisu opažene promjene u sigurnosti.
Of the 496 patients exposed to Kentera in the randomised, double-blind, placebo-controlled 12-week study and the 14-week safety extension study, 188 patients (38%) were 65 years of age and older.
Od 496 pacijenata izloženih Kenteri u randomiziranom, dvostruko slijepom, placebo kontroliranom 12-tjednom ispitivanju i u 14-tjednom sigurnosnom nastavku ispitivanja 188 bolesnika (38%) bilo je staro 65 godina ili više.
Of the 5 cases reported, 3 were associated with excessive alcohol intake, 1 was associated with biliary sludge, and in one case the patient discontinued eluxadoline 2 weeks prior to the onset of symptoms.
Od 5 prijavljenih slučajeva, 3 su bila povezana s pretjeranim unosom alkohola, 1 je bio povezan sa žučnim muljem, a u jednom slučaju bolesnik je prestao uzimati eluksadolin 2 tjedna prije javljanja simptoma.
Of the 511 patients receiving ofatumumab in clinical trials, 139 patients (27%) experienced an adverse event associated with a decreased neutrophil count; 118 (23%) of the 511 patients experienced
Od 511 bolesnika liječenih ofatumumabom u kliničkim ispitivanjima, u njih 139 (27%) pojavila se nuspojava povezana sa smanjenim brojem neutrofila; 118 (23%) od 511 bolesnika imalo je nuspojavu
Of the 511 patients receiving ofatumumab in clinical trials, 300 patients (59%) experienced an infection.
Od 511 bolesnika liječenih ofatumumabom u kliničkim ispitivanjima, njih 300 (59%) imalo je infekciju.
Of the 52 patients described above that were included in Study CAC-91-10-10 during the 17-year study period, 6 died, 3 had no evidence of treatment, 4 terminated the study, 10 were lost to follow-up, and for 1 data retrieval was unsuccessful.
Od 52 prethodno opisana bolesnika koji su uključeni u ispitivanje CAC-91-10-10 tijekom 17- godišnjeg razdoblja ispitivanja, 6 ih je preminulo, 3 nije imalo dokaza o liječenju, 4 je završilo ispitivanje, 10 je izgubljeno iz praćenja, a za 1 bolesnika nisu uspješno prikupljeni podaci.
Of the 52 patients described above that were included in Study CAC-91-10-10 during the 17-year study period, 6 died, 3had no evidence of treatment, 4 terminated the study, 10 were lost to follow-up, and for 1 data retrieval was unsuccessful.
Od 52 prethodno opisana bolesnika koji su uključeni u ispitivanje CAC-91-10-10 tijekom 17- godišnjeg razdoblja ispitivanja, 6 ih je preminulo, 3 nije imalo dokaza o liječenju, 4 je završilo ispitivanje, 10 je izgubljeno iz praćenja, a za 1 bolesnika nisu uspješno prikupljeni podaci.
Of the 52 patients identified, 36 patients were in the CP CML subpopulation (21 who had previously received 2 prior TKIs and 15 who had received 1 prior TKI).
Od 52 identificirana bolesnika, 36 bolesnika bilo je u subpopulaciji s CP KML-om (od kojih je 21 prethodno primio 2 TKI-a, a 15 je prethodno primilo 1 TKI).
Of the 54 patients withdrawn from ORENCIA during the double-blind period for up to 6 months, none had an infusion reaction upon re-initiation of ORENCIA.
Od 54 bolesnika koji nisu primali lijek ORENCIA tijekom dvostruko slijepe faze u trajanju do 6 mjeseci, niti jedan nije imao infuzijsku reakciju kod ponovnog uvođenja lijeka ORENCIA.
Of the 540 patients in, 61% were male, 43% were ≥ 65 years (median age was 62 years [range 15-89]) and 98% were white.
Od 540 bolesnika, njih 61% bili su muškarci, 43% imali su ≥65 godina (medijan dobi iznosio je 62 godine [raspon: 15-89]), a 98% bolesnika bili su bijelci.
Of the 55 patients who reported suicidal ideation or behaviour, 48 (24 varenicline, 24 placebo) were from the two trials that enrolled patients with a history of schizophrenia/ schizoaffective disorder, or of depression.
Od 55 bolesnika koji su prijavili suicidalne ideje ili ponašanje, 48 (24 na vareniklinu, 24 na placebu) ih je bilo iz dva ispitivanja koja su uključivala bolesnike sa shizofrenijom/shizoafektivnim poremećajem ili depresijom u anamnezi.
Of the 571 ankylosing spondylitis patients exposed to Cosentyx in clinical studies, a total of 24 patients were 65 years of age or older and 3 patients were 75 years of age or older.
Od 571 bolesnika s ankilozantnim spondilitisom izloženih Cosentyxu u kliničkim ispitivanjima, ukupno je 24 bolesnika bilo u dobi od 65 i više godina, a 3 bolesnika bila su u dobi od 75 i više godina.
Of the 6026 total number of patients in clinical studies of Repatha, 1779 (30%) were ≥ 65 years old, while 223 (4%) were ≥ 75 years old.
U kliničkim ispitivanjima s lijekom Repatha, od ukupno 6026 bolesnika, njih 1779 (30%) bilo je u dobi od ≥ 65 godina, dok je njih 223 (4%) bilo u dobi od ≥ 75 godina.
Of the 611 patients treated with the ZALTRAP/FOLFIRI regimen in the pivotal study of MCRC patients, 172 (28.2%) were aged ≥65 and <75 and 33 (5.4%) were age ≥75.
Od 611 bolesnika liječenih protokolom ZALTRAP/FOLFIRI u pivotalnom ispitivanju u bolesnika s MKRK-om, njih 172 (28,2%) bila su u dobi ≥ 65 i < 75 godina, a 33 bolesnika (5,4%) bila su u dobi od ≥ 75 godina.
Of the 681 (78%) patients that experienced diarrhoea, 665 patients had drug-related events of diarrhoea and 8 patients discontinued bosutinib due to this event.
Od 681 (78%) bolesnika koji su imali proljev, 665 bolesnika imalo je događaje proljeva povezane uz lijek, a 8 bolesnika prekinulo je liječenje bosutinibom zbog tog događaja.
Of the 704 patients evaluated in the MM-009 and MM-010 studies, 44.6% were aged 65 or over.
Od 704 bolesnika koji su procijenjeni u ispitivanju MM-009 i MM-010, 44,6% bilo je u dobi od 65 godina ili više.
Of the 714 patients, 642 were with mild hepatic impairment, 67 with moderate hepatic impairment, and 2 with severe hepatic impairment.
714 bolesnika, 642 su bili s blagim oštećenjem jetre, 67 s umjerenim oštećenjem jetre i 2 s teškim oštećenjem jetre.
Of the 72 patients randomised to Cosentyx 150 mg, 45 and 35 had an ASAS 20/40 response, respectively.
Od 72 bolesnika randomiziranih na Cosentyx 150 mg, 45 odnosno 35 imalo je odgovor ASAS 20/40.
Of the 722 patients in the trial, the majority of patients had HER2-negative disease (90%), with a small number of patients with unknown (8%) or confirmed HER2-positive status (2%), who had previously been treated with or were considered unsuitable for trastuzumab therapy.
Od 722 bolesnika koji su sudjelovali u ispitivanju većina je imala HER2- negativan oblik bolesti (90%), uz mali broj bolesnika u kojih status nije bio poznat (8%) ili su imali potvrđen HER2-pozitivan status (2%), te su prethodno ili bili liječeni trastuzumabom ili nisu bili smatrani pogodnima za liječenje trastuzumabom.
Of the 760 randomised patients, the median age was 61 years, 61% were male, 78% were Caucasian, and all patients had baseline ECOG Performance Status (PS) of 0 or 1.
Od 760 randomiziranih bolesnika, medijan dobi bio je 61 godina, 61% bili su muškarci, 78% bili su bijelci, a svi su bolesnici imali početno ECOG funkcionalno stanje (PS) 0 ili 1.
Of the 783 patients initially randomised to active treatment in RA-I, 508 completed 52 weeks of placebo- controlled treatment and entered the open-label extension study.
Od 783 bolesnika koji su na početku randomizirani za aktivno liječenje u RA-I 508 je završilo placebom kontrolirano liječenje u trajanju od 52 tjedna te se uključilo u otvoreni produžetak istraživanja.
Of the 783 patients initially randomised to active treatment in RA-I, 508 completed 52 weeks of placebo- controlled treatment and entered the open-label extension study.
Od 783 bolesnika koji su početno randomizirani za aktivno liječenje u RA-I 508 je završilo placebom kontrolirano liječenje u trajanju od 52 tjedna te se uključilo u otvoreni nastavak studije.
Of the 87 patients treated with Epclusa + RBV, 85 patients were included in the analysis of NS5A RAVs; 2 patients were excluded as they neither achieved SVR12 nor had virologic failure.
Od 87 bolesnika liječenih lijekom Epclusa + RBV, 85 bolesnika su bila uključena u analizu NS5A RAV- ova; dva bolesnika bila su isključena jer nisu postigli SVR12 niti virološki neuspjeh.
Of the 94 patients with cirrhosis at baseline (Ishak fibrosis score: 5 - 6), 26% (24) experienced no change in Ishak fibrosis score and 72% (68) experienced regression of cirrhosis by week 240 with a reduction in Ishak fibrosis score of at least 2 points.
Od 94 pacijenata s cirozom na početku (5-6 bodova na Ishakovoj ljestvici fibroze), 26% (24) nije imalo nikakve promjene u rezultatu na Ishakovoj ljestvici fibroze, a 72% (68) je imalo regresiju ciroze do 240. tjedna i snižen rezultat na Ishakovoj ljestvici fibroze za najmanje 2 boda.
Of the 974 psoriatic arthritis patients exposed to Cosentyx in clinical studies, a total of 85 patients were 65 years of age or older and 4 patients were 75 years of age or older.
Od 974 bolesnika s psorijatičnim artritisom izloženih Cosentyxu u kliničkim ispitivanjima, ukupno je 85 bolesnika bilo u dobi od 65 ili više godina, 4 bolesnika bila su u dobi od 75 i više godina.
Of the 981 patients treated with IMBRUVICA for B-cell malignancies, 5% discontinued treatment primarily due to adverse reactions.
Od 981 bolesnika liječenog lijekom IMBRUVICA zbog B-staničnih malignih bolesti, 5% je prekinulo liječenje prvenstveno radi nuspojava.
Of the 981 patients treated with IMBRUVICA, 62% were 65 years of age or older.
Od 981 bolesnika liječenih lijekom IMBRUVICA, 62% je imalo 65 ili više godina.
Of the administered rivaroxaban dose, approximately 2/3 undergoes metabolic degradation, with half then being eliminated renally and the other half eliminated by the faecal route.
Oko 2/3 primijenjene doze rivaroksabana metabolički se razgradi, od čega se oko polovina eliminira bubrezima, a druga polovina putem crijeva.
Of the animals receiving adjuvanted vaccine, 87% and 96% were protected against the lethal homologous or heterologous challenge, respectively.
Od životinja koje su primile cjepivo s adjuvansom, njih 87% bilo je zaštićeno od letalnog homolognog, a njih 96% od letalnog heterolognog opterećenja.
of the calcium channel blockers
titraciju doze blokatora kalcijevih
Of the cases of MDS disease progression to AML that were observed, patients with RAEB-1 classification of MDS at baseline were more likely to have disease progression to AML (see section 4.4).
Kod slučajeva progresije MDS bolesti u AML, bolesnici s RAEB-1 početnom klasifikacijom MDS-a imali su veću vjerojatnost progresije bolesti u AML (vidjeti dio 4.4).
Of the control arm patients, 64% crossed over to receive an investigational autologous cellular immunotherapy manufactured from cells cryopreserved at the time the control was manufactured; patients were not randomised to subsequent autologous cellular immunotherapy.
U kontrolnoj skupini bolesnika, 64% ih je primilo eksperimentalnu autolognu staničnu imunoterapiju dobivenu od stanica krioprezerviranih u trenutku kada je kontrolni lijek proizveden; bolesnici nisu randomizirani za naknadnu autolognu staničnu imunoterapiju.
Of the CP-CML patients previously treated with one, two, three or four prior TKIs, 75% (12/16), 67% (66/98), 45% (64/141), and 58% (7/12)) achieved a MCyR while on Iclusig, respectively.
Od bolesnika u kroničnoj fazi KML koji su prethodno liječeni s jednim, dva, tri ili četiri TKI, 75% (12/16), 67% (66/98), 45% (64/141) odnosno 58% (7/12) postigli su MCyR dok su se liječili lijekom Iclusig.
Of the CP-CML patients with no mutation detected at entry, 49% (66/136) achieved a MCyR.
Od ukupnog broja bolesnika u kroničnoj fazi KML bez mutacija prilikom uključivanja, 49% (66/136) postiglo je MCyR.
of the external auditory canal
lušnog kanala
Of the hepatic AEs, increased ALT and AST were the most common events and the majority were either Grade 1 or 2.
Najčešći jetreni štetni događaji bile su povišene razine ALT-a i AST-a, koje su većinom bile 1. ili 2. stupnja.
Of the HIV-1 isolates from 10 patients with resistance development in the Genvoya group, the mutations that emerged were M184V/I (n = 9) and K65R/N (n = 2) in RT and T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1) and N155H (n = 2) in integrase.
U HIV-1 izolatima od 10 bolesnika s razvojem virusne rezistencije u skupini liječenoj lijekom Genvoya nastale mutacije bile su M184V/I (n = 9) i K65R/N (n = 2) u RT te T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1) i N155H (n = 2) u integrazi.
Of the HIV-1 isolates from 8 patients with resistance development in the E/C/F/TDF group, the mutations that emerged were M184V/I (n = 6) and K65R/N (n = 3) in RT and E92E/Q (n = 2), and Q148R (n = 2), and N155H/S (n = 2) in integrase.
U HIV-1 izolatima od 8 bolesnika s razvojem virusne rezistencije u skupini liječenoj E/C/F/TDF nastale mutacije bile su M184V/I (n = 6) i K65R/N (n = 3) u RT te E92/Q (n = 2), Q148R (n = 2) i N155H/S (n = 2) u integrazi.
Of the individuals taking Truvada, 0.8% (13 out of 1,576) tested positive for HIV-1 infection over 1 year compared with 3.3% (52 out of 1,578) of those taking placebo.
Tijekom jedne godine, 0,8 % osoba koje su uzimale lijek Truvada (13 od 1 576) bile su pozitivne na infekciju virusom HIV-1, u usporedbi s 3,3 % osoba koje su primale placebo (52 od 1 578).
Of the infliximab- treated patients who received at least one shortened infusion, infusion-related reactions occurred in 15% of patients and serious infusion reactions occurred in 0.4% of patients.
Među bolesnicima liječenima infliksimabom koji su primili barem jednu infuziju u skraćenom trajanju, reakcije povezane s infuzijom javile su se u njih 15%, dok su se ozbiljne reakcije na infuziju javile u 0,4% bolesnika.
of the methadone dose may be
možda će biti potrebna kada se istodobno
Of the most commonly reported, the following events occurred more often with Ranexa (placebo-corrected frequencies) in elderly ( 75 years of age) than younger patients (< 75 years of age): constipation (8% versus 5%), nausea (6% versus 3%), hypotension (5% versus 1%), and vomiting (4% versus 1%).
Među najčešće zabilježenim nuspojavama, slijedeće su se nuspojave pojavljivale češće kod primjene Ranexe (učestalosti su korigirane u odnosu na placebo) kod starijih ( 75 godina života) nego kod mlađih bolesnika (< 75 godina života): konstipacija (8% u odnosu na 5%), mučnina (6% u odnosu na 3%), hipotenzija (5% u odnosu na 1%), i povraćanje (4% u odnosu na 1%).
Of the need for the procedures/tests before and during teriflunomide treatment
informacije o potrebi provođenja pretraga/testova prije i tijekom liječenja teriflunomidom
Of the older subjects, 64 % were influenza-positive and of those with chronic cardiac and/or respiratory disease 62 % were influenza-positive.
Među starijim ispitanicima bilo je 64 % influenca- pozitivnih, a među onima s kroničnim srčanim ili respiratornim oboljenjima bilo je 62 % influenca- pozitivnih.
Of the other 4 cases, detailed information was missing.
U preostala 4 slučaja nije bilo detaljnih informacija.
Of the patients given Otezla in these two studies, 33% (168 of 562) and 29% (79 of 274) responded to treatment.
Od svih bolesnika koji su primili lijek Otezla u ova dva ispitivanja, 33% (168 od 562) i29% (79 od 274) odgovorilo je na terapiju u usporedbi s 5% (15 od
Of the patients randomised to the chemotherapy arm, 48% crossed over and subsequently received treatment with pembrolizumab.
Među bolesnicima randomiziranima za primanje kemoterapije, njih 48% prešlo je u drugu skupinu i nakon toga primalo liječenje pembrolizumabom.
Of the patients who achieved at least a 20% reduction of parenteral nutrition at Weeks 20 and 24 in the initial study, 75% sustained this response on Revestive after up to 1 year of continuous treatment.
Među bolesnicima koji su u prvotnom ispitivanju postigli smanjenje parenteralne prehrane od barem 20% u tjednima 20 i 24, 75% je održalo odgovor na lijek Revestive do 1 godine kontinuiranog liječenja.
Of the patients who did not convert to sinus rhythm, the incidence of bradycardia events in the first 2 hours post-dose was similar in placebo and vernakalant treated groups (4.0% and 3.8%, respectively).
Među bolesnicima u kojih nije nastupila konverzija u sinusni ritam, incidencija bradikardije u prva 2 sata nakon primjene doze bila je slična u skupini koja je primala placebo (4,0%) i onoj koja je primala vernakalant (3,8%).
Of the patients who did not meet stability criteria for the individual components, 12 of 15 Cerdelga patients and 3 of 3 Cerezyme patients remained within therapeutic goals for GD1.
Od bolesnika koji nisu zadovoljili kriterije stabilnosti za pojedine komponente, 12 od 15 bolesnika liječenih lijekom Cerdelga i 3 od 3 bolesnika liječenih lijekom Cerezyme ostalo je unutar terapijskih ciljeva za GD1.
Of the patients who had been clinically diagnosed with MCI at study entry, 9 (19%) converted to clinical AD 36 months later.
Među bolesnicima kojima je na početku ispitivanja klinički dijagnosticiran MCI u njih 9 (19%) je nakon 36 mjeseci dijagnosticiran klinički AB.
Of the patients who lost adequate response after re-randomization to placebo who then enrolled into the open-label extension trial, 38% (25/66) and 55% (36/66) regained PASI 75 response after 12 and 24 weeks of re-treatment, respectively.
Među bolesnicima u kojih je nastupio gubitak primjerenog odgovora nakon ponovne randomizacije u skupinu koja je primala placebo, a koji su potom uključeni u otvoreni produžetak ispitivanja, odgovor PASI 75 ponovno je postignut u 38% (25/66) bolesnika nakon 12 tjedana terapije, odnosno u 55% (36/66) bolesnika nakon 24 tjedna terapije.
Of the patients who received Simponi, 51% (74 out of 146) had 20% reductions after 14 weeks, compared with 9% of patients who were given placebo (10 out of 113).
51 % bolesnika (74 od 146) koji su primili lijek Simponi imalo je 20 %-tno smanjenje nakon 14 tjedana, u usporedbi s 9 % bolesnika koji su primili placebo (10 od 113).
Of the patients who received Simponi, 59% (82 out of 138) had 20% reductions after 14 weeks, compared with 22% of patients who were given placebo (17 out of 78).
59% bolesnika (82 od 138) koji su primili lijek Simponi imalo je 20 %-tno smanjenje nakon 14 tjedana, u usporedbi s 22 % bolesnika koji su primili placebo (17 od 78).
Of the patients who received Simponi, 71% (69 out of 97) had 20% reductions after 16 weeks, compared with 40% of patients who were given placebo (40 out of 100).
71% bolesnika (69 od 97) koji su primili lijek Simponi imalo je 20 %-tno smanjenje nakon 16 tjedana, u usporedbi s 40% bolesnika koji su primili placebo (40 od 100).
Of the patients who reported flu-like symptoms 90% reported them as mild or moderate in severity.
Od bolesnika koji su prijavili simptome nalik gripi, 90% ih je prijavilo kao blage ili umjerene težine.
Of the patients with at least a PASI-50 response who were re-randomized to placebo at Week 32, 24.2% were PASI-50 responders at Week 52.
Od bolesnika s odgovorom najmanje PASI-50, koji su u 32. tjednu ponovno randomizirani na placebo, 24,2% imalo je odgovor PASI-50 u 52. tjednu.
of the PDE-5 inhibitor to
doze PDE-5 inhibitora kako
of the plasma levels of lopinavir is
potrebnom, valja pratiti vrijednosti
of the reductions in
značaj smanjenja
Of the rheumatoid arthritis patients evaluated for antinuclear antibodies (ANA), the percentage of patients who developed new positive ANA (≥ 1:40) was higher in patients treated with etanercept (11%) than in placebo- treated patients (5%).
Među bolesnicima s reumatoidnim artritisom u kojih su određivana antinuklearna protutijela (ANA) veći je postotak novopozitivnih na ANA (≥1:40) bio među onima liječenima etanerceptom (11%) nego među onima koji su primali placebo (5%).
Of the rheumatoid arthritis patients evaluated for antinuclear antibodies (ANA), the percentage of patients who developed new positive ANA (1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated patients (5%).
Među bolesnicima s reumatoidnim artritisom u kojih su određivana antinuklearna protutijela (ANA) veći je postotak novopozitivnih na ANA (≥ 1:40) bio među onima liječenima Enbrelom (11%) nego među onima koji su primali placebo (5%).
Of the rheumatoid arthritis patients evaluated for antinuclear antibodies (ANA), the percentage of patients who developed new positive ANA (1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated patients (5%).
Među bolesnicima s reumatoidnim artritisom u kojih su određivana antinuklearna protutijela (ANA) veći je postotak novopozitivnih na ANA (≥ 1:40) bio među onima liječenima Enbrelom (11%),nego među onima koji su primali placebo (5%).
OF THE SIGHT AND REACH OF CHILDREN
DOHVATA DJECE
OF THE SIGHT AND REACH OF CHILDREN
POSEBNO UPOZORENJE O ČUVANJU LIJEKA IZVAN POGLEDA I DOHVATA DJECE
Of the specimens from the non-clinical and clinical studies (n = 876) that were mutation positive by the THxID BRAF assay and subsequently were sequenced using the reference method, the specificity of the assay was 94%.
Iz uzoraka iz nekliničkih i kliničkih ispitivanja (N=876) koji su bili pozitivni na mutaciju prema THxID BRAF testu i kasnije su sekvencionirani primjenom referentne metode, specifičnost testa iznosila je 94%.
Of the specimens from the non-clinical and clinical studies (n=876) that were mutation positive by the THxID BRAF assay and subsequently were sequenced using the reference method, the specificity of the assay was 94%.
Iz uzoraka iz nekliničkih i kliničkih ispitivanja (N=876) koji su bili pozitivni na mutaciju prema THxID BRAF testu i kasnije su sekvencionirani korištenjem referentne metode, specifičnost testa je iznosila 94%.
Of the subjects with observed data at Week 16 in the four Phase 3 clinical trials, 50.8% of those randomized to receive naltrexone / bupropion had lost ≥5% of their baseline body weight, compared to 19.3% of placebo-treated subjects (Week 16 Responders).
Od ispitanika s opaženim podacima 16. tjedna u četiri klinička ispitivanja faze 3, 50,8 % randomiziranih za primanje naltrekson / bupropiona izgubilo je ≥ 5 % svoje početne tjelesne težine, u usporedbi s 19,3 % u ispitanika koji su primali placebo (koji su odgovorili na liječenje u 16. tjednu).
Of the total 123 patients, 26 patients died; each of these deaths could be attributed either as a complication of the index event or associated with co-morbidities.
Od ukupno 123 bolesnika 26 bolesnika je preminulo; svaka od tih smrti može se pripisati bilo komplikaciji navedenog događaja ili povezati s komorbiditetima.
Of the total 128 patients who entered part I taking corticosteroids, 92 attempted corticosteroid tapering.
Od ukupno 128 bolesnika koji su ušli u prvi dio uzimajući kortikosteroide, 92 je pokušalo smanjiti dozu kortikosteroida.
Of the total 25 subjects: 9 received placebo, 9 received mepolizumab 75 mg intravenously, and 7 received 100 mg subcutaneously.
Od ukupno 25 ispitanika: 9 ih je primalo placebo, 9 je primalo mepolizumab u dozi od 75 mg intravenski, a 7 mepolizumab u dozi od 100 mg supkutano.
Of the total number of patients in clinical studies of dabrafenib (N=578), 22% were 65 years of age and older, and 6% were 75 years of age and older.
Od ukupnog broja ispitanika u kliničkim ispitivanjima dabrafeniba (N=578), 22% je imalo 65 i više godina, a 6% imalo je 75 godina i više.
Of the total number of patients in clinical studies of osimertinib (N=411), 46% were 65 years of age and older, of whom 13% were 75 years of age and older.
Od ukupnog broja bolesnika u kliničkim ispitivanjima osimertiniba (N=411), 46% je bilo u dobi od 65 i više godina, od čega je 13% bilo u dobi od 75 i više godina.